PTC Therapeutics, Inc. Amortization of Intangible Assets
PTC Therapeutics, Inc. (PTCT) reported Amortization of Intangible Assets of $11.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-07-30
- PTC Therapeutics, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $11.84M, a 191.58% increase year-over-year.
- PTC Therapeutics, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $11.58M, a 204.92% increase year-over-year.
- PTC Therapeutics, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $9.35M, a 182.70% increase year-over-year.
- PTC Therapeutics, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $7.53M, a 148.16% increase year-over-year.
- PTC Therapeutics, Inc. amortization of intangible assets for fiscal 2025 was $24.74M, a 59.26% decline from fiscal 2024.
- PTC Therapeutics, Inc. amortization of intangible assets for fiscal 2024 was $60.74M, a 72.72% decline from fiscal 2023.
- PTC Therapeutics, Inc. amortization of intangible assets for fiscal 2023 was $222.63M, a 91.01% increase from fiscal 2022.
- PTC Therapeutics, Inc. amortization of intangible assets for fiscal 2022 was $116.55M, a 112.88% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.84M 10-Q · filed 2026-07-30 | $23.42M 10-Q · filed 2026-07-30 | $32.77M derived: sum of 3 quarters · filed 2026-07-30 | $40.30M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $11.58M 10-Q · filed 2026-05-07 | $20.93M derived: sum of 2 quarters · filed 2026-05-07 | $28.46M derived: sum of 3 quarters · filed 2026-05-07 | $32.52M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $9.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $16.88M derived: sum of 2 quarters · filed 2026-02-19 | $20.94M derived: sum of 3 quarters · filed 2026-07-30 | $24.74M 10-K · filed 2026-02-19 |
| 2025-09-30 | $7.53M 10-Q · filed 2025-11-04 | $11.60M derived: sum of 2 quarters · filed 2026-07-30 | $15.39M 10-Q · filed 2025-11-04 | $18.70M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $4.06M 10-Q · filed 2026-07-30 | $7.86M 10-Q · filed 2026-07-30 | $11.17M derived: sum of 3 quarters · filed 2026-07-30 | $14.20M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $3.80M 10-Q · filed 2026-05-07 | $7.11M derived: sum of 2 quarters · filed 2026-05-07 | $10.14M derived: sum of 3 quarters · filed 2026-05-07 | $13.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $6.34M derived: sum of 2 quarters · filed 2026-02-19 | $9.21M derived: sum of 3 quarters · filed 2026-02-19 | $60.74M 10-K · filed 2026-02-19 |
| 2024-09-30 | $3.04M 10-Q · filed 2025-11-04 | $5.90M derived: sum of 2 quarters · filed 2025-11-04 | $57.43M 10-Q · filed 2025-11-04 | $134.60M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $2.87M 10-Q · filed 2025-08-07 | $54.40M 10-Q · filed 2025-08-07 | $131.57M derived: sum of 3 quarters · filed 2026-02-19 | $190.22M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $51.53M 10-Q · filed 2025-05-06 | $128.70M derived: sum of 2 quarters · filed 2026-02-19 | $187.35M derived: sum of 3 quarters · filed 2026-02-19 | $234.75M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $77.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $135.82M derived: sum of 2 quarters · filed 2026-02-19 | $183.22M derived: sum of 3 quarters · filed 2026-02-19 | $222.63M 10-K · filed 2026-02-19 |
| 2023-09-30 | $58.65M 10-Q · filed 2024-11-07 | $106.05M derived: sum of 2 quarters · filed 2024-11-07 | $145.46M 10-Q · filed 2024-11-07 | $181.22M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $47.40M 10-Q · filed 2024-08-08 | $86.81M 10-Q · filed 2024-08-08 | $122.58M derived: sum of 3 quarters · filed 2025-02-27 | $153.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $39.41M 10-Q · filed 2024-04-25 | $75.18M derived: sum of 2 quarters · filed 2025-02-27 | $106.20M derived: sum of 3 quarters · filed 2025-02-27 | $132.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $35.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $66.79M derived: sum of 2 quarters · filed 2025-02-27 | $93.08M derived: sum of 3 quarters · filed 2025-02-27 | $116.55M 10-K · filed 2025-02-27 |
| 2022-09-30 | $31.02M 10-Q · filed 2023-10-26 | $57.32M derived: sum of 2 quarters · filed 2023-10-26 | $80.79M 10-Q · filed 2023-10-26 | $97.13M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $26.29M 10-Q · filed 2023-08-03 | $49.77M 10-Q · filed 2023-08-03 | $66.11M derived: sum of 3 quarters · filed 2024-02-29 | $80.49M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $23.47M 10-Q · filed 2023-04-27 | $39.81M derived: sum of 2 quarters · filed 2024-02-29 | $54.20M derived: sum of 3 quarters · filed 2024-02-29 | $66.95M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $16.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $30.72M derived: sum of 2 quarters · filed 2024-02-29 | $43.47M derived: sum of 3 quarters · filed 2024-02-29 | $54.75M 10-K · filed 2024-02-29 |
| 2021-09-30 | $14.38M 10-Q · filed 2022-10-27 | $27.13M derived: sum of 2 quarters · filed 2022-10-27 | $38.41M 10-Q · filed 2022-10-27 | $48.99M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $12.75M 10-Q · filed 2022-08-04 | $24.03M 10-Q · filed 2022-08-04 | $34.61M derived: sum of 3 quarters · filed 2023-02-21 | $44.24M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $11.28M 10-Q · filed 2022-05-03 | $21.86M derived: sum of 2 quarters · filed 2023-02-21 | $31.49M derived: sum of 3 quarters · filed 2023-02-21 | $40.22M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $10.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $20.21M derived: sum of 2 quarters · filed 2023-02-21 | $28.94M derived: sum of 3 quarters · filed 2023-02-21 | $36.89M 10-K · filed 2023-02-21 |
| 2020-09-30 | $9.63M 10-Q · filed 2021-10-28 | $18.36M derived: sum of 2 quarters · filed 2021-10-28 | $26.31M 10-Q · filed 2021-10-28 | $34.28M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $8.73M 10-Q · filed 2021-07-29 | $16.68M 10-Q · filed 2021-07-29 | $24.65M derived: sum of 3 quarters · filed 2022-02-22 | $31.68M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $7.95M 10-Q · filed 2021-05-04 | $15.92M derived: sum of 2 quarters · filed 2022-02-22 | $22.95M derived: sum of 3 quarters · filed 2022-02-22 | $29.52M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $7.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $15.00M derived: sum of 2 quarters · filed 2022-02-22 | $21.57M derived: sum of 3 quarters · filed 2022-02-22 | $27.65M 10-K · filed 2022-02-22 |
| 2019-09-30 | $7.03M 10-Q · filed 2020-10-29 | $13.60M derived: sum of 2 quarters · filed 2020-10-29 | $19.68M 10-Q · filed 2020-10-29 | $25.74M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $6.58M 10-Q · filed 2020-08-05 | $12.65M 10-Q · filed 2020-08-05 | $18.71M derived: sum of 3 quarters · filed 2021-02-25 | $24.51M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $6.08M 10-Q · filed 2020-04-30 | $12.14M derived: sum of 2 quarters · filed 2021-02-25 | $17.93M derived: sum of 3 quarters · filed 2021-02-25 | $23.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $11.86M derived: sum of 2 quarters · filed 2021-02-25 | $17.45M derived: sum of 3 quarters · filed 2021-02-25 | $22.88M 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.79M 10-Q · filed 2019-10-30 | $11.39M derived: sum of 2 quarters · filed 2019-10-30 | $16.82M 10-Q · filed 2019-10-30 | $22.24M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $5.59M 10-Q · filed 2019-08-06 | $11.02M 10-Q · filed 2019-08-06 | $16.45M derived: sum of 3 quarters · filed 2020-03-02 | $26.16M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $5.43M 10-Q · filed 2019-05-02 | $10.86M derived: sum of 2 quarters · filed 2020-03-02 | $20.57M derived: sum of 3 quarters · filed 2020-03-02 | $20.57M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $5.43M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $15.14M derived: sum of 2 quarters · filed 2020-03-02 | $15.14M derived: sum of 3 quarters · filed 2020-03-02 | $15.38M 10-K · filed 2020-03-02 |
| 2017-09-30 | $9.72M 10-Q · filed 2018-11-05 | $9.72M derived: sum of 2 quarters · filed 2018-11-05 | $9.95M 10-Q · filed 2018-11-05 | $9.72M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-01 | $0.00 derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 derived: sum of 3 quarters · filed 2019-03-01 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 10-K · filed 2019-03-01 | |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-02 | $0.00 10-Q · filed 2017-11-02 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |